Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Up to 30% of psoriasis patients develop psoriatic arthritis (PsA), yet predicting who's at risk remains elusive. Researchers are now combining AI, ultrasound, biomarkers, and smartphone apps to catch PsA earlier — or stop it altogether. A clinical trial is even testing whether a biologic drug can prevent the transition from psoriasis to PsA.
Up to 30% of people with psoriasis will develop psoriatic arthritis (PsA), but the median time from symptom onset to diagnosis is still around 2.5 years — a window where significant joint damage can occur. While risk factors like family history, obesity, nail dystrophy, and scalp lesions are well known, existing prediction models haven't been precise enough to reliably identify who will make the leap from skin disease to joint disease.
Researchers are now pushing toward a new concept: disease interception — identifying and treating high-risk patients before full-blown PsA develops. Tools in the pipeline include the PRESTO-PsA risk calculator (estimating 1- to 5-year PsA risk), the DUET ultrasound scoring system for early enthesitis detection, AI-powered EHR models, and smartphone apps that passively track movement and symptoms. A major European study, HIPPOCRATES, has enrolled over 9,000 psoriasis patients to validate new biomarker-based prediction models. Meanwhile, the PAMPA trial is testing whether the IL-23 inhibitor guselkumab can actually prevent the transition from psoriasis to PsA.
Key Takeaways:
Why it matters: Earlier detection and potential prevention of PsA could spare patients years of undiagnosed joint inflammation and irreversible damage — a meaningful shift from reactive to proactive rheumatologic care.
